Live News Categoriesmarket

MGNX.O (MGNX.O) News

Follow MGNX.O (MGNX.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol MGNX.O Asset market Sector Markets 90 days 1 Updated Oct 15, 2026, 08:09 PM UTC Open live news feed

L MacroGenics Doses First Patient in Phase 1 Trial of MGC030 for Advanced Solid Tumors MacroGenics dosed the first patient in a Phase 1 trial of MGC030 for advanced solid tumors, announced Oct. 15, 2026. The antibody-drug conjugate becomes its third ADC in active clinical development. Preclinical findings NEWS | Oct 15, 2026, 08:09 PM UTC